Ascendis Pharma A/S SVP & PAO Exercises Warrants and Sells Ordinary Shares

Transaction Overview

On September 8, 2026, Mads Bodenhoff, Senior Vice President & Principal Accounting Officer of Ascendis Pharma A/S ($ASND), completed a warrant exercise and subsequent sale of Ordinary Shares:

1. Derivative Exercise (Code M): Exercised 3,000 warrants at an exercise price of $110.00 per share to acquire 3,000 Ordinary Shares.
2. Open Market Sale (Code S): Sold all 3,000 acquired Ordinary Shares at a price of $270.19 per share, generating gross proceeds of $810,570.00.

Following these transactions, Mr. Bodenhoff holds 0 directly owned Ordinary Shares and 687 remaining unexercised warrants.

Significance & Market Context

• Routine Option/Warrant Monetization: This transaction reflects a standard exercise-and-sell strategy where acquired shares are immediately disposed of on the open market.
• Significance Level: Low — Routine executive compensation realization without direct changes to underlying core equity positions outside of derivative expirations/vesting.